OncoMatch/Clinical Trials/NCT05958121
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Is NCT05958121 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including IMA402 (Phase Ia) and IMA402 (Phase Ib) for refractory cancer.
Treatment: IMA402 (Phase Ia) · IMA402 (Phase Ib) · IMA402 (Phase II) — The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: * To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I) * To characterize the safety and tolerability of IMA402 (Phase I/II) * To evaluate anti-tumor activity of IMA402 (Phase II) Secondary objectives: * To evaluate the initial anti-tumor activity of IMA402 (Phase I) * To evaluate anti-tumor activity of IMA402 (Phase II) * To describe the PK of IMA402 (Phase I/II)
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all available indicated standard-of-care treatments
Patients must have received or not be eligible for all available indicated standard-of-care treatments
Lab requirements
Blood counts
adequate baseline hematologic function
Kidney function
adequate baseline renal function
Liver function
adequate baseline hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify